Key points are not available for this paper at this time.
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
Harvard University
Massachusetts General Hospital
Seoul National University
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Baselga et al. (Wed,) studied this question.